Long Term Antipsychotic Use In Kids Okay With FDA, But Panel Has Concerns

Not only did three antipsychotic drugs receive FDA advisory committee endorsement June 10 for the acute treatment of schizophrenia and bipolar disorder in pediatric populations, but FDA said that if the sNDAs are approved, it will likely extrapolate pediatric maintenance claims from the adult data